摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氨基-N-Cbz-吡咯烷 | 185057-50-5

中文名称
3-氨基-N-Cbz-吡咯烷
中文别名
3-氨基-N-CBZ-吡咯烷盐酸盐;N-CBZ-3-氨基吡咯烷;3-氨基吡咯烷-1-甲酸苄酯;1-苄氧羰基-3-氨基吡咯烷
英文名称
benzyl 3-aminopyrrolidine-1-carboxylate
英文别名
(S)-3-Amino-1-pyrrolidinecarboxylic acid,phenylmethyl ester
3-氨基-N-Cbz-吡咯烷化学式
CAS
185057-50-5
化学式
C12H16N2O2
mdl
——
分子量
220.271
InChiKey
FPXJNSKAXZNWMQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    351.7±42.0 °C(Predicted)
  • 密度:
    1.186±0.06 g/cm3(Predicted)
  • 稳定性/保质期:

    避氧化物和空气

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    55.6
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090

SDS

SDS:4758c46bba51a529c847849c39e812d7
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: benzyl 3-aminopyrrolidine-1-carboxylate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

Section 3. Composition/information on ingredients.
Ingredient name: benzyl 3-aminopyrrolidine-1-carboxylate
CAS number: 185057-50-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H16N2O2
Molecular weight: 220.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Naphthyridine antibacterial agents containing an .alpha.-amino acid in
    摘要:
    本文描述了一种新型喹诺酮和萘啶类抗菌剂,其在体内口服和皮下注射时具有改善的活性,这些化合物的7-侧链含有α-氨基酸;同时描述了其对应的光学异构体,制备方法以及治疗感染性疾病的组合物和方法。
    公开号:
    US04851418A1
  • 作为产物:
    描述:
    2,3-二氢吡咯-1-羧酸苄酯 在 iridium(lll) bis[2-(2,4-difluorophenyl)-5-methylpyridine-N,C20]-4,40-di-tert-butyl-2,20-bipyridine hexafluorophosphate 、 2,4,6-Triisopropylthiophenol 作用下, 以 甲醇甲苯 为溶剂, 反应 16.0h, 以72%的产率得到3-氨基-N-Cbz-吡咯烷
    参考文献:
    名称:
    氨基甲酸酯与胺,氨和NH杂环的光催化加氢胺化反应合成β-二胺结构单元。
    摘要:
    3-氨基取代的饱和氮杂环是β-二胺的重要亚类,它出现在许多临床药物中。在本文中,我们报告了基于脲选择性光氧化还原介导的氨基甲酸酯加氢胺化处理这些产品的统一方法。胺偶联配偶体可以在一组反应条件下涵盖多种胺类型,包括伯烷基胺,氨,芳基和杂芳基胺以及NH杂环。该方法能够合成多种药学上相关的结构单元。
    DOI:
    10.1002/chem.202003562
点击查看最新优质反应信息

文献信息

  • [EN] ARYLAMINE SUBSTUTUTED BICYCLIC HETEROAROMATIC COMPOUNDS AS P38 KINASE INHIBITORS<br/>[FR] COMPOSES BICYCLIQUES HETEROAROMATIQUES ARYLAMINE SUBSTITUEE UTILISES EN TANT QU'INHIBITEURS DE KINASE P38
    申请人:CELLTECH R&D LTD
    公开号:WO2004000846A1
    公开(公告)日:2003-12-31
    Bicyclic heteroaromatic derivatives of formula (1) are described: F (1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a -N= atom or a -C(Rb)= group, or the dashed line is absent and A is a -N(Rb)-, or -C(Rb)(Rc)- group; X is an -O-, -S- or substituted nitrogen atom or a -S(O)-, -S(O2)- or -NH­-group; Y is a nitrogen or substituted carbon atom or a -CH= group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the remaining substituents are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
    公式(1)描述了具有双环杂芳衍生物:F(1)其中:连接A和C(Ra)的虚线存在且表示键,A是一个-N=原子或一个-C(Rb)=基团,或者虚线不存在且A是一个-N(Rb)-或-C(Rb)(Rc)-基团;X是一个-O-,-S-或取代的氮原子或一个-S(O)-,-S(O2)-或-NH­-基团;Y是一个氮或取代的碳原子或一个-CH=基团;n为零或整数1;Alk1是一个可选择取代的脂肪或杂原脂肪链L1是一个共价键或连接原子或基团;Cy1是一个氢原子或一个可选择取代的环脂肪,多环脂肪,杂环脂肪,多杂环脂肪,芳香或杂芳基团;Ar是一个可选择取代的芳香或杂芳基团;其余取代基在规范中定义。这些化合物是p38激酶的有效和选择性抑制剂,并可用于预防和治疗免疫或炎症性疾病。
  • [EN] THIENOPYRIDONE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES DE THIENOPYRIDONE EN TANT QU'INHIBITEURS DE KINASE
    申请人:CELLTECH R&D LTD
    公开号:WO2004113348A1
    公开(公告)日:2004-12-29
    A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-3-yl, pyrrolidin-3-ylamino or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.
    一系列在2位被羰基或磺酰基连接的吡咯烷-3-基、吡咯烷-3-基或相关基团取代的噻吩[2,3-b]吡啶-6(7H)-酮衍生物,作为p38 MAP激酶的抑制剂,在医学上具有用途,例如在治疗和/或预防免疫或炎症性疾病方面。
  • [EN] COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE<br/>[FR] COMPOSÉS DESTINÉS À TRAITER ET À PRÉVENIR LA MALADIE PROVOQUÉE PAR LE VIRUS RESPIRATOIRE SYNCYTIAL
    申请人:HOFFMANN LA ROCHE
    公开号:WO2013053658A1
    公开(公告)日:2013-04-18
    A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1, R2 and X are as defined in description and in claims, can be used as a medicament.
    公式(I)的化合物以及其中所述的药用可接受盐,其中R1、R2和X如描述和权利要求中所定义,可用作药物。
  • Copper‐Catalyzed Deaminative Difluoromethylation
    作者:Xiaojun Zeng、Wenhao Yan、Samson B. Zacate、Aijie Cai、Yufei Wang、Dongqi Yang、Kundi Yang、Wei Liu
    DOI:10.1002/anie.202006048
    日期:2020.9.14
    stable bioisostere of an amino (NH2) group. Therefore, methods that can rapidly convert an NH2 group into a CF2H group would be of great value to medicinal chemistry. We report herein an efficient Cu‐catalyzed approach for the conversion of alkyl pyridinium salts, which can be readily synthesized from the corresponding alkyl amines, to their alkyl difluoromethane analogues. This method tolerates a broad
    甲基(CF 2 H)被认为是基(NH 2)基团的亲脂性和代谢稳定的生物等排体。因此,能够将NH 2基快速转化为CF 2 H基的方法对药物化学具有重要的价值。我们在此报告了一种有效的催化方法,用于将烷基吡啶鎓盐(可以轻松地从相应的烷基胺合成)转化为其烷基二氟甲烷类似物。该方法可耐受多种官能团,可用于复杂的含基药物的后期修饰。
  • Design, synthesis and SAR of antitubercular benzylpiperazine ureas
    作者:Sohal Satish、Rohan Chitral、Amitkumar Kori、Basantkumar Sharma、Jayashree Puttur、Afreen A. Khan、Deepali Desle、Kavita Raikuvar、Aaron Korkegian、Elvis A. F. Martis、Krishna R. Iyer、Evans C. Coutinho、Tanya Parish、Santosh Nandan
    DOI:10.1007/s11030-020-10158-3
    日期:2022.2
    With the aim of delineating the SAR associated with (I), fifty-five analogs were synthesized and screened against Mtb. The SAR suggests that the piperazine ring, benzyl urea and piperonyl moieties are essential signatures of this series. Active compounds in this series are metabolically stable, have low cellular toxicity and are valuable leads for optimization. Molecular docking suggests these molecules
    摘要 GSK Tres Cantos 的科学家披露的N-糠基哌嗪被选为来自表型全细胞筛选的抗分枝杆菌。用苯环取代 GSK Tres Cantos 分子中的呋喃环产生的分子 ( I ) 对Mtb H37Rv 的 MIC 为 1 μM,细胞毒性低(HepG2 IC 50  ~ 80 μM),良好的 DMPK 特性和特异性山地车_ 为了描绘与 ( I ) 相关的 SAR,合成了 55 种类似物并针对Mtb进行了筛选. SAR 表明哌嗪环、苄基和胡椒基部分是该系列的基本特征。该系列中的活性化合物代谢稳定,细胞毒性低,是优化的宝贵线索。分子对接表明这些分子像 Q203 一样占据 QcrB 的 Q0 位点。 图形摘要 N-糠基哌嗪-1-羧酰胺的生物等排替代产生了分子 (I) 一种具有令人满意的 PD、代谢和毒性特征的新型先导。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫